JAK-Inhibitors – A Story of Success and Adverse Events

References

• Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–1108. doi:10.1016/S0140-6736(10)60826-4
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108–1123. doi:10.1002/art.41752
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RB, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheumatic Dis. 2023;82(1):3–18. doi:10.1136/ard-2022-223356
   PubMed Web of Science ®Google Scholar
• Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology. 2019;58(6):953–962. doi:10.1093/rheumatology/key339
   PubMed Web of Science ®Google Scholar
• Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022;14(5):1001. doi:10.3390/pharmaceutics14051001
   PubMed Web of Science ®Google Scholar
• Wilks A, Harpur A, Kurban R, Ralph S, Zürcher G, Ziemiecki A. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol. 1991;11(4):2057–2065. doi:10.1128/mcb.11.4.2057-2065.1991
   PubMed Web of Science ®Google Scholar
• Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon αβ signaling pathway. Cell. 1992;70(2):313–322. doi:10.1016/0092-8674(92)90105-L
   PubMed Web of Science ®Google Scholar
• Philips RL, Wang Y, Cheon H, et al. The JAK-STAT pathway at 30: much learned, much more to do. Cell. 2022;185(21):3857–3876. doi:10.1016/j.cell.2022.09.023
   PubMed Web of Science ®Google Scholar
• Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298(5600):1912–1934. doi:10.1126/science.1075762
   PubMed Web of Science ®Google Scholar
• Müller M, Briscoe J, Laxton C, et al. The protein tyrosine kinase JAK1 complements defects in interferon-α/β and-γ signal transduction. Nature. 1993;366(6451):129–135. doi:10.1038/366129a0
   PubMed Web of Science ®Google Scholar
• Hubbard SR. Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase. Front Endocrinol. 2017;8:361. doi:10.3389/fendo.2017.00361
   PubMed Web of Science ®Google Scholar
• Kung JE, Jura N. Prospects for pharmacological targeting of pseudokinases. Nat Rev Drug Discov. 2019;18(7):501–526. doi:10.1038/s41573-019-0018-3
   PubMed Web of Science ®Google Scholar
• Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci. 2018;27(12):1984–2009. doi:10.1002/pro.3519
   PubMed Web of Science ®Google Scholar
• Koppikar P, Bhagwat N, Kilpivaara O, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012;489(7414):155–159. doi:10.1038/nature11303
   PubMed Web of Science ®Google Scholar
• Liu C, Kieltyka J, Fleischmann R, Gadina M, O’Shea JJ. A Decade of JAK Inhibitors: what Have We Learned and What May Be the Future? Arthritis Rheumatol. 2021;73(12):2166–2178. doi:10.1002/art.41906
   PubMed Web of Science ®Google Scholar
• Vincenti F, Tedesco Silva H, Busque S, et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant. 2012;12(9):2446–2456. doi:10.1111/j.1600-6143.2012.04127.x
   PubMed Web of Science ®Google Scholar
• Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60(7):1895–1905. doi:10.1002/art.24567
   PubMed Web of Science ®Google Scholar
• Fleischmann R. Recent issues in JAK inhibitor safety: perspective for the clinician. Expert Rev Clin Immunol. 2022;18(3):295–307. doi:10.1080/1744666X.2022.2039122
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–326. doi:10.1056/NEJMoa2109927
   PubMed Web of Science ®Google Scholar
• FDA requires warnings about increased risk of serious heart related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions – update 12/2021. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed February 22, 2024.
   Google Scholar
• EMA Assessment Report Xeljanz; 2017 EMA/CHMP/853224/2016 Committee for Medicinal Products for Human Use (CHMP). https://www.ema.europa.eu/en/documents/assessment-report/xeljanz-epar-public-assessment-report_en.pdf. Accessed February 22, 2024.
   Google Scholar
• EMA Janus Kinase Inhibitors (JAKi) – EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. 10 March 2023 – EMA/142279/2023 2023.
   Google Scholar
• Singh JA. Risks and Benefits of Janus Kinase Inhibitors in Rheumatoid Arthritis - Past, Present, and Future. N Engl J Med. 2022;386(4):387–389. doi:10.1056/NEJMe2117663
   PubMed Web of Science ®Google Scholar
• Khosrow-Khavar F, Desai RJ, Lee H, Lee SB, Kim SC. Tofacitinib and Risk of Malignancy: results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study. Arthritis Rheumatol. 2022;74(10):1648–1659. doi:10.1002/art.42250
   PubMed Web of Science ®Google Scholar
• Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022;81(6):798–804. doi:10.1136/annrheumdis-2021-221915
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Danese S, Yndestad A, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023;82(7):901–910. doi:10.1136/ard-2022-223715
   PubMed Web of Science ®Google Scholar
• Solomon DH, Reed GW, Kremer JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67(6):1449–1455. doi:10.1002/art.39098
   PubMed Web of Science ®Google Scholar
• Curtis JR, Yamaoka K, Chen YH, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023;82(3):331–343. doi:10.1136/ard-2022-222543
   PubMed Web of Science ®Google Scholar
• Giles JT, Sattar N, Gabriel S, et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. 2020;72(1):31–40. doi:10.1002/art.41095
   PubMed Web of Science ®Google Scholar
• Taylor PC, Atzeni F, Balsa A, Gossec L, Müller-Ladner U, Pope J. The Key Comorbidities in Patients with Rheumatoid Arthritis: a Narrative Review. J Clin Med. 2021;10(3):509. doi:10.3390/jcm10030509
   PubMed Web of Science ®Google Scholar
• Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107(9):1303–1307. doi:10.1161/01.CIR.0000054612.26458.B2
   PubMed Web of Science ®Google Scholar
• Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71(9):1524–1529. doi:10.1136/annrheumdis-2011-200726
   PubMed Web of Science ®Google Scholar
• Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology. 2014;53(12):2143–2154. doi:10.1093/rheumatology/keu224
   PubMed Web of Science ®Google Scholar
• Liao KP. Cardiovascular disease in patients with rheumatoid arthritis. Trends Cardiovasc Med. 2017;27(2):136–140. doi:10.1016/j.tcm.2016.07.006
   PubMed Web of Science ®Google Scholar
• Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326–332. doi:10.1136/annrheumdis-2014-205675
   PubMed Web of Science ®Google Scholar
• England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018;361:k1036. doi:10.1136/bmj.k1036
   PubMed Web of Science ®Google Scholar
• Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008;26(5 Suppl 51):56.
   Web of Science ®Google Scholar
• Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690–1697. doi:10.1002/art.24092
   PubMed Web of Science ®Google Scholar
• Choi HK, Rho YH, Zhu Y, Cea-Soriano L, Aviña-Zubieta JA, Zhang Y. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Ann Rheum Dis. 2013;72(7):1182–1187. doi:10.1136/annrheumdis-2012-201669
   PubMed Web of Science ®Google Scholar
• Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther. 2014;16(5):435. doi:10.1186/s13075-014-0435-y
   PubMed Web of Science ®Google Scholar
• Molander V, Bower H, Frisell T, Askling J. Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Ann Rheum Dis. 2021;80(2):169–175. doi:10.1136/annrheumdis-2020-218419
   PubMed Web of Science ®Google Scholar
• Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheumatic Dis. 2020;79(11):1400–1413. doi:10.1136/annrheumdis-2019-216761
   PubMed Web of Science ®Google Scholar
• Desai RJ, Pawar A, Khosrow-Khavar F, Weinblatt ME, Kim SC. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology. 2021;61(1):121–130. doi:10.1093/rheumatology/keab294
   PubMed Web of Science ®Google Scholar
• Salinas CA, Louder A, Polinski J, et al. Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: a Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases. Rheumatol Ther. 2023;10(1):201–223. doi:10.1007/s40744-022-00505-1
   PubMed Web of Science ®Google Scholar
• Lund JL, Richardson DB, Stürmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221–228. doi:10.1007/s40471-015-0053-5
   PubMedGoogle Scholar
• Taylor PC, Takeuchi T, Burmester GR, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022;81(3):335–343. doi:10.1136/annrheumdis-2021-221276
   PubMed Web of Science ®Google Scholar
• Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17(1):212. doi:10.1186/s13075-015-0728-9
   PubMed Web of Science ®Google Scholar
• Mellemkjaer L, Linet MS, Gridley G, Frisch M, Møller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer. 1996;32(10):1753–1757. doi:10.1016/0959-8049(96)00210-9
   Google Scholar
• Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R45. doi:10.1186/ar2404
   PubMed Web of Science ®Google Scholar
• Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692–701. doi:10.1002/art.21675
   PubMed Web of Science ®Google Scholar
• Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362–1370. doi:10.1016/j.amjcard.2011.06.054
   PubMed Web of Science ®Google Scholar
• Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(4):576–582. doi:10.1136/ard.2010.129916
   PubMed Web of Science ®Google Scholar
• Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum. 2009;60(11):3180–3189.
   PubMed Web of Science ®Google Scholar
• Huss V, Bower H, Wadström H, Frisell T, Askling J. Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. Rheumatology. 2022;61(5):1810–1818. doi:10.1093/rheumatology/keab570
   PubMed Web of Science ®Google Scholar
• Burmester GR, Cohen SB, Winthrop KL, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9(1):e002735. doi:10.1136/rmdopen-2022-002735
   PubMed Web of Science ®Google Scholar
• Russell MD, Stovin C, Alveyn E, et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis. 2023;82(8):1059–1067. doi:10.1136/ard-2023-224049
   PubMed Web of Science ®Google Scholar